Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.2704
-0.0026-0.95%
Post-market: 0.27390.0035+1.29%19:41 EDT
Volume:2.31M
Turnover:631.99K
Market Cap:28.39M
PE:-0.09
High:0.2860
Open:0.2850
Low:0.2610
Close:0.2730
52wk High:3.39
52wk Low:0.1611
Shares:105.00M
Float Shares:89.28M
Volume Ratio:0.80
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8900
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-209.03%
PB:-0.74
PE(LYR):-0.15

Loading ...

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Benzinga_recent_news
·
Apr 08

Outlook Therapeutics submits formal dispute resolution request to FDA

TIPRANKS
·
Apr 07

BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision

Reuters
·
Apr 07

BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA

Reuters
·
Apr 07

Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds

Reuters
·
Mar 26

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Dow Jones
·
Mar 26

Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced

MT Newswires Live
·
Mar 25

Outlook Therapeutics prices USD 5 million public offering at USD 0.25 per share with warrants

Reuters
·
Mar 24

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

THOMSON REUTERS
·
Mar 24

BRIEF-Outlook Therapeutics Announces Proposed Public Offering

Reuters
·
Mar 24

Outlook Therapeutics launches best-efforts public offering of common stock and warrants

Reuters
·
Mar 24

Outlook Therapeutics Launches LYTENAVA in Germany and the UK

Reuters
·
Mar 24

Outlook Therapeutics Inc - Extends Maturity Date of Existing Convertible Note to December 31, 2026

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Enters $18.4 Mln New Note, Expects $17 Mln Net Proceeds

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Lender Confirms Existing Note Is Not in Default

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Proceeds From New Note to Pay Down Existing Note, $10.8 Mln Principal and Interest Remaining on Existing Note

THOMSON REUTERS
·
Mar 16

Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Dow Jones
·
Mar 16

Outlook Therapeutics director Julia A. Haller to step down effective March 10, 2026

Reuters
·
Mar 12

Outlook Therapeutics provides update following FDA meeting on ONS-5010

TIPRANKS
·
Mar 06

Outlook Therapeutics Updates on FDA Type A Meeting for ONS-5010/LYTENAVA BLA

Reuters
·
Mar 06